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early Ovariectomy results in 
reduced numbers of cD11c+/
cD11b+ spleen cells and impacts 
Disease expression in Murine lupus
Melissa A. Cunningham* , Jena R. Wirth , Jennifer L. Scott , Jackie Eudaly , Erin L. Collins 
and Gary S. Gilkeson
Division of Rheumatology and Immunology, Ralph H. Johnson Veterans Affairs Hospital, Medical University of South 
Carolina, Charleston, SC, USA
Ninety percent of those diagnosed with systemic lupus erythematosus are female, with 
peak incidence between the ages of 15 and 45, when women are most hormonally 
active. Despite significant research effort, the mechanisms underlying this sex bias 
remain unclear. We previously showed that a functional knockout of estrogen receptor 
alpha (ERα) resulted in significantly reduced renal disease and increased survival in 
murine lupus. Dendritic cell (DC) development, which requires both estrogen and ERα, is 
impacted, as is activation status and cytokine production. Since both estrogen and tes-
tosterone levels have immunomodulating effects, we presently studied the phenotype of 
NZM2410 lupus-prone mice following post- and prepubertal ovariectomy (OVX) ± estra-
diol (E2) replacement to determine the impact of hormonal status on disease expression 
and DC development in these mice. We observed a trend toward survival benefit in 
addition to decreased proteinuria and improved renal histology in the early OVX, but not 
late OVX- or E2-repleted WT mice. Interestingly, there was also a significant difference in 
splenic DC subsets by flow cytometry. Spleens from NZM mice OVX’d early had a signif-
icant decrease in proinflammatory CD11c+CD11b+ DCs (vs. unmanipulated WTs, late 
OVX- and E2-repleted mice). These early OVX’d animals also had a significant increase 
in tolerogenic CD11c+CD8a+ DCs vs. WT. These data join a growing body of evidence 
that supports a role for hormone modulation of DCs that likely impacts the penetrance 
and severity of autoimmune diseases, such as lupus.
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inTrODUcTiOn
Systemic lupus erythematosus (SLE) is the prototypic autoimmune disease characterized by produc-
tion of autoantibodies and immune complex-mediated end-organ damage. Nine out of 10 patients 
diagnosed with lupus are female, thus biologic sex is important in disease development. The cause of 
the sex difference in SLE is likely multifactorial, including the sex chromosomes, sex hormones, and 
their receptors. Perhaps the strongest epidemiological data to support a role for hormone impact on 
disease is the fact that incidence of disease is highest during the reproductive years when women are 
most hormonally active (in contrast to pre-menarche and post-menopause, when lupus incidence is 
February 2016 | Volume 7 | Article 312
Cunningham et al. Early OVX Decreases cDCs in Murine Lupus
Frontiers in Immunology | www.frontiersin.org
lower and the female:male ratio is less profound). The SELENA 
trial showed that use of oral contraceptive pills in SLE patients did 
not enhance flare rates; however, estrogen replacement therapy 
in post-menopausal women did result in a slight increase in mild 
lupus flares, indicating that changing/replacing estrogen levels in 
an estrogen-deficient setting can impact disease (1, 2).
In murine models of lupus, manipulation of sex hormones also 
has significant impact on disease expression. NZB/NZW mice 
and some of the derived NZM strains, including NZM2410, have 
significant female predominance of disease (3). Both genders of 
MRL/lpr mice develop severe lupus; however, there is a trend 
toward earlier and more severe disease in females (4). In classic 
experiments by Roubinian et  al. and later by Tarkowski et  al., 
manipulation of sex hormones and castration led to significant 
effects on disease expression (5–10). Specifically, castration of 
male NZB/NZW or MRL/lpr mice led to female-like disease and 
ovariectomy (OVX) with androgen replacement in female mice 
led to disease protection. Protection in male mice was limited to 
those in which gonadectomy was performed at 4 weeks of age or 
earlier (prepubertal). Interestingly, castration after onset of sexual 
maturity had little impact on disease. Administration of phar-
macological doses of estrogen led to significant enhancement of 
disease in ovariectomized females, castrated males, and unma-
nipulated females (6). These experiments are suggestive that there 
is an imprinted component to female sex that is fixed at the time 
of sexual maturity. This imprinting appears manipulatable since 
lupus can be induced by repleting estrogen. Once the imprinting 
has occurred, however, taking away estrogen does not appear to 
be an effective therapeutic intervention, although there is modest 
data to support androgens as a treatment.
Estrogen has pleiotropic effects on many different cell types, 
including immune cells. For example, estrogen treatment of 
macrophages is proinflammatory and induces expression/release 
of TNFα and nitric oxide (NO) (11–16). In contrast, estrogen 
given to macrophage in the setting of LPS treatment results in 
estrogen partially inhibiting the release of NO and TNFα (15). 
This estrogen-mediated immune suppression was mediated via 
the activation of ERα. Short-term administration of exogenous 
estrogen appears immune suppressing, while long-term exog-
enous or endogenous estrogen is proinflammatory (17). In some 
lupus-prone strains, exogenous estradiol, via ERα, promotes 
survival of DNA-reactive B cells and decreases the activation 
threshold for BCR signaling, leading to increased autoantibody 
formation (18–20). While the ability of estrogen to impact B cell 
activation requires classic ERα action, estrogen effects on B cell 
survival do not (21). This may also explain data in NZM2410 
ERαKO female mice that have high levels of both serum estradiol 
and anti-dsDNA but are still protected from renal disease and 
have a significant survival benefit (4). It seems clear that estrogen 
and ERα have differential effects on immune cells that may also 
be dose and time dependent.
In lupus, dendritic cells (DCs) play a critical role in disease 
pathogenesis and progression. For example, mice deficient in 
DCs (conventional DCs and most plasmacytoid DCs) are pro-
tected from developing lupus nephritis. DC-deficient mice have 
similar autoantibody levels and immune complex deposition 
as their WT littermates, but lack progression of renal damage 
despite ongoing immune complex deposition. As noted above, we 
previously showed that female NZM2410 ERαKO mice also had 
significantly less renal disease and prolonged survival compared 
to WT littermates despite similar serum levels of autoantibodies 
and glomerular immune complex deposition. We subsequently 
showed that DCs from ERαKO mice have a blunted inflamma-
tory response (e.g., IL-6, IL-1β, and IFNα production) to toll-like 
receptor (TLR) ligands (22). These findings suggested that an 
important effect of estrogen and ERα in lupus may be on the 
innate immune system and local tissue response to inflammation.
Despite significant research effort, the mechanisms underly-
ing estrogen and its receptors effects on disease remain unclear. 
Since estrogen and ERα are known to modulate DC development 
in  vitro (23–26), we and others are interested in the impact of 
estrogen on DCs in SLE, especially since estrogen influences DC 
development and function primarily via ERα (24, 26). Due to the 
importance of DCs in SLE pathogenesis, we investigated the effect 
of early and late OVX ± estradiol (E2) repletion on both lupus 
disease phenotype and DC development in NZM2410 mice.
MaTerials anD MeThODs
Mice
Mice were maintained at the Ralph H. Johnson VAMC Animal 
Facility (Charleston, SC, USA). Animal protocols followed 
the principles outlined in the Guide for the Care and Use of 
Laboratory Animals, and were approved by MUSC’s IACUC. The 
NZM2410 mouse strain was acquired from Jackson Laboratory 
(Bar Harbor, ME, USA) and was maintained on a 12-h light/dark 
cycle with access to food and water ad libitum. All experimental 
mice (n = 34) were female and littermates where possible. Mice 
were ovariectomized at 4 or 8 weeks of age. One group of mice 
OVX’d at 4 weeks of age subsequently received 0.1 mg, 90-day time 
release 17β estradiol pellet (Innovative Research, Sarasota, FL, 
USA, Catalog number: NE-121) that was implanted subdermally. 
Mice were sacrificed with isoflurane and cervical dislocation at 
32  weeks of age or when they reached sacrifice requirements 
(>10% loss of weight, >500  mg urine protein as assessed by 
dipstick, or upon recommendation by the animal facility).
serum anti-dsDna, serum estradiol, and 
serum Testosterone
Serum was collected throughout the experiment and at time 
of sacrifice. Serum anti-dsDNA was measured by ELISA assay, 
as previously described (4). Estradiol levels were assessed via 
ELISA (Calbiotech, San Diego, CA, USA), with an assay sensitiv-
ity of 3 pg/ml; precision: 3.1% (intra-assay), 9.9% (inter-assay). 
Testosterone serum levels were assessed by radioimmunoassay 
(RIA) at the University of Virginia Center for Research and 
Reproduction Ligand Assay and Analysis core.
Urine Protein excretion
Mice were housed in metabolic cages for 24 urine hour col-
lection at 2-week intervals starting at 10 weeks of age until 
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sacrifice. To prevent bacterial growth, antibiotics (ampicillin 
25 μg/ml, gentamicin 50 μg/ml, and chloramphenicol 200 μg/
ml) were added to the collection tube. After 24  h, urine 
quantity was determined and samples were frozen at −20 
for future analysis via mouse albumin ELISA with known 
standards.
spleen and Kidney Processing and renal 
Pathology
Spleens were harvested and kept on ice during processing. The 
spleens were processed through 40 μm strainers and depleted of 
red blood cells with red blood cell lysis buffer (144 mM NH4Cl 
and 17 mM Tris, pH 7.6). Spleen cells were washed twice with 
cold RPMI before being stained for flow cytometry analysis.
One kidney was divided evenly for renal pathology and 
immunofluorescence. One half was snap frozen in liquid nitrogen 
and stored at −80°C for immunofluorescence analysis, the other 
half was fixed with buffered formalin, embedded in paraffin, 
and then sectioned and stained with hematoxylin and eosin. 
Kidney sections were analyzed in a blinded fashion by Dr. Phillip 
Ruiz (Department of Pathology, University of Miami School of 
Medicine, Miami, FL, USA) and graded on glomerular hypercel-
lularity, segmental mesangial expansion, neutrophils/cell debris, 
crescent formation, and necrosis. These grades were combined 
for a total glomerular and interstitial pathology score. Deposition 
of IgG and complement component C3 was analyzed on the half 
kidney snap frozen in liquid nitrogen. Deposition was assessed by 
immunofluorescence by incubating slides with rabbit anti-mouse 
IgG FITC (Sigma) and sheep anti-mouse C3 FITC (Sigma). IgG 
and C3 were graded 0–3 for intensity of staining, as previously 
described (4).
staining and Flow cytometry
Spleen cells (4  ×  106 per sample) were isolated in staining 
buffer (0.5% BSA and 0.02% sodium azide in 1× PBS) and 
stained with CD11c-Brilliant violet 605 (1:100), CD8a-
Brilliant violet 421 (1:100), and CD11b-PE (1:400). Cells 
were incubated with antibodies for 30 min on ice in the dark. 
All antibodies were purchased from Biolegend (San Diego, 
CA, USA). Viability was assessed using LIVE/DEAD Fixable 
Dead Cell stain (Life Technologies, Carlsbad, CA, USA) at 
a concentration of 50  μl/million cells. Cells were washed 
twice with staining buffer and resuspended in 0.3  ml of 
staining buffer for flow cytometry. Cells were acquired on 
an LSRFortessa cell analyzer (BD Biosciences, San Jose, CA, 
USA), and analysis was performed using FlowJo software 
(FlowJo LLC, Ashland, OR, USA).
statistical analysis
Kruskal–Wallis one-way analysis of variance and post hoc Dunn’s 
multiple comparison test were utilized to test for significance 
when comparing treatment groups. SEMs were reported where 
applicable. p Values ≤0.05 were considered significant. Log rank 
analysis was used to compare trends in animal survival.
resUlTs
effects of early vs. late Ovariectomy on 
survival, Body, and Organ Weights in 
nZM2410 Mice
NZM2410 mice underwent four different treatments: (1) no OVX 
and no E2 pellet (NONP), (2) late OVX at 8 weeks (post-puberty) 
with no E2 pellet (O8NP), (3) early OVX at 4 weeks (pre-puberty) 
with no E2 pellet (O4NP), or (4) early OVX at 4  weeks with 
0.1 mg E2 via sustained release pellet (O4 + E2). Similar to our 
previous work (4), unmanipulated NZM2410 (NONP) female 
mice began to die at 23 weeks of age and only 33% survived to 
32 weeks (study endpoint). In contrast, as shown in Figure 1, 71% 
of mice OVX’d before puberty (O4NP) survived to 32 weeks of 
age. Mice that were either OVX’d late (post-puberty), or early 
but estradiol repleted (O4 + E2) were less protected, with only 
42 and 50% surviving to 32 weeks of age, respectively. Overall, 
there was not a significant difference in survival between the 
four treatment groups (Figure 1A). At the time of sacrifice, all 
mice were weighed and total body, spleen, and kidney weights 
were documented. Neither OVX nor presence of E2 pellet sig-
nificantly altered the weights of treated mice compared to the 
unmanipulated NONP mice (Figure 1B). Spleen weights were 
variable within all four treatment groups, but no significant dif-
ferences were observed between groups (Figure 1C). Although 
O4NP mice trended toward lower kidney weights compared to 
the other groups (Figure  1D), there was again no significant 
difference observed. Overall, OVX with or without E2 repletion 
did not significantly alter disease penetrance in NZM2410 mice; 
however, early OVX did appear to impact disease and offer mod-
est protection.
serum anti-dsDna autoantibody and 
Proteinuria levels in OVX’d nZM2410
Terminal anti-double stranded DNA (dsDNA) antibody levels 
were assessed via ELISA. O8NP mice had anti-dsDNA levels 
similar to unmanipulated NZM. Interestingly, we observed 
increased anti-dsDNA levels in both groups of early OVX’d mice, 
which was significantly different in the O4NP mice (vs. O8NP) 
(Figure 2B). Similar results were observed in anti-dsDNA levels 
at the 18-week time point (Figure 2A). At 18 weeks of age, when 
onset of lupus-like kidney disease typically becomes evident in 
NZM2410 mice, 08NP and O4 +  E2 mice had not developed 
proteinuria by albumin ELISA; unexpectedly, several O4NP mice 
had early levels of proteinuria, similar to unmanipulated NZM 
mice at that time point (data not shown). Nephritis in these mice 
did not progress; in fact, proteinuria in the same three O4NP 
animals was slightly reduced at the terminal time point. In the 
other WT mice, terminal albuminuria levels increased over time 
as expected reflecting an increased number of animals developing 
lupus renal disease (Figure 3A). It was unexpected to find both 
higher levels of anti-dsDNA and earlier onset of proteinuria in 
the O4NP animals (which had the best overall survival), and sug-
gested that early OVX resulted in a disease phenotype that is less 
severe/less progressive, rather than delayed in onset.
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FigUre 1 | health parameters in nZM2410 mice. NZM2410 lupus-prone mice were unmanipulated (NONP, n = 12), OVX’d after puberty (O8NP, n = 7), OVX’d 
before puberty (O4NP, n = 7), or OVX’d before puberty and administered estrogen (O4 + E2, n = 7). (a,B) No significant difference in survival or body weight 
between the four groups was observed, although there was a trend toward survival benefit in the O4NP group (71%) vs. WT NONP (33%). (c) No significant 
difference in spleen weights between NZM2410 WTs based on hormonal milieus was observed, although there was a trend toward bigger spleens in OVX’d mice. 
(D) No significant difference in kidney weights between-treatment groups, but a trend toward reduced kidney weight in O4NP vs. O4 + E2 was noted (p = 0.07).
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e2 effects on renal Pathology in  
nZM2410 Mice
Kidneys were collected at time of sacrifice and sectioned. C3 and 
IgG deposition, markers of kidney involvement in lupus disease, 
were determined by C3 and IgG immunofluorescence (IF). IF 
intensity was semiquantitated using a 0–3 scale by a blinded 
scorer. For both C3 and IgG, all four treatment groups scored a 2 
or greater, indicating moderate to high levels of immune complex 
deposition that was not significantly different between groups 
(Figures 3B,D). H&E stained kidney samples were prepared and 
renal pathology scores were determined by a blinded pathologist 
who used multiple standard parameters to assess disease involve-
ment of glomeruli, tubules, interstitium, and vessels. In agreement 
with the improved survival and reduced levels of terminal 
proteinuria observed, O4NP mice appeared to have less severe 
kidney disease by renal pathology score compared to the other 
treatment groups, although this decrease was not statistically sig-
nificant (Figure 3C). Overall, all four groups showed evidence of 
renal disease by proteinuria, deposition scores, and overall renal 
pathology scores, although O4NP mice were modestly protected.
hormone levels in nZM2410 Mice with 
and without e2
Estradiol levels in mice can range from <5 pg/ml (old, sick, or non-
breeding) to >1000 pg/ml (young pregnant). In this study, serum 
17β estradiol levels for all treatment groups were assessed by the 
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FigUre 2 | anti-double stranded Dna levels in nZM2410. (a) 18-week 
anti-dsDNA levels did not show any significant differences among treatment 
groups. All NZM mouse groups had elevated levels compared to the negative 
control, a C57BL/6J mouse that produces no autoantibodies. (B) At the 
terminal endpoint, O4NP mice had significantly increased levels of dsDNA 
compared to O8NP. Elevated anti-dsDNA levels from O4NP mice also 
trended towards significance when compared to unmanipulated NZM 
(p = 0.07). All results shown as mean ± SE with statistical analysis done by 
Kruskal–Wallis non-parametric test with post hoc Dunn’s multiple comparison 
test, p < 0.05.
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current gold standard 17β-estradiol ELISA (27). The O4 + E2 treat-
ment group was OVX’d and had estrogen replaced via subcutane-
ous E2 pellet to account for potential effects of varying endogenous 
estrogen levels in cycling NZM2410 mice. The E2 pellet in O4 + E2 
maintained an average of 3.8 pg/ml estrogen during the experiment, 
significantly higher than estrogen levels in the OVX’d unrepleted 
treatment groups, as expected (Figure 4A). O4 + E2 mice main-
tained a level of physiological estrogen that is normally seen in 
mouse strains, with one individual having a much higher level of 
estrogen than the rest of the cohort. NONP mice had low normal 
estrogen levels which could be caused by a variety of factors includ-
ing age, disease state, and hormonal cycle, since NZM2410 begin 
to manifest disease symptoms as early as 16 weeks of age. Terminal 
testosterone levels were quantified with RIA. NONP mice trended 
toward higher levels of testosterone, as would be expected in gonad-
intact cycling female mice, compared to the three OVX’d treatment 
groups, but no significant differences were observed (Figure 4B).
Flow cytometry
Dendritic cells are dysregulated in SLE in both human disease 
and murine models of lupus. Since estrogen is required for 
normal DC development, we investigated the impact of post- vs. 
prepubertal OVX  ±  estrogen on DC numbers in lupus-prone 
NZM2410 mice. DC numbers were analyzed by flow cytometry 
using ex vivo splenocytes harvested at the time of sacrifice. We 
found that the O4NP mice, which tended toward a survival 
benefit, had a significant reduction in the number of CD11c+/
CD11b+ cells (vs. NONP, O8NP, and O4 + E2) (Figure 5A). This 
was particularly surprising in the case of the profound difference 
between O4NP and O8NP, where the only difference between 
groups was the timing of the OVX, suggesting that hormone levels 
during pubescence are critical to determining the developmental 
program of hematopoietic progenitors. This concept is further 
supported by the increase in a different myeloid subset (CD11c+/
CD8a+) from spleens of O4NP mice vs. NONP (Figure  5B). 
Importantly, CD11c+/CD8a+ DCs have been associated with 
promotion of regulatory T cells and mediation of tolerance in 
multiple tissue types and may partially explain the trend toward 
disease protection in the O4NP mice.
DiscUssiOn
Sex biases in autoimmunity have been observed in both humans 
and in rodent models of disease (28). SLE is a disease with a 
profound sex bias. Although there are data to support a role for 
sex chromosomes, sex hormones, and their receptors in disease 
expression, a clear etiology for this health disparity is not appar-
ent. It is known that both estrogens and androgens can modulate 
the expression of autoimmunity. As in human disease, the strik-
ing sex difference in most murine lupus strains includes females 
developing earlier, more severe disease. This can be modified in 
both sexes by castration and differential hormone replacement, 
and the timing of this appears to affect disease differentially in 
males (10, 29–31). While there is somewhat conflicting data 
from prior studies of OVX, estrogen replacement, and estrogen 
receptor knockout on autoimmunity and immune functions 
in lupus animals, there is more agreement on the generally 
protective role for androgens in disease expression. In seminal 
work by Roubinian et al., prepubertal castration of male NZB/
NZW F1 (B/W) lupus-prone mice resulted in accelerated disease 
development, with both accelerated autoantibody production 
and mortality. In contrast, prepubertal castration of female mice 
did not change mortality, although it did have minor effects on 
autoantibody production and class switching (10). The effect on 
castrated males and females was much greater when they were 
treated with androgen vs. estrogen therapy, which resulted in 
attenuated kidney disease and improved survival when castrated 
females were treated with androgen, while castrated male B/W 
mice treated with estrogen had accelerated disease severity simi-
lar to that of WT females (29). Thus, androgen was protective 
while estrogen promoted disease. Anti-estrogen treatment with 
tamoxifen has also been shown to reduce autoantibody produc-
tion and mortality in B/W mice (32, 33). These studies were some 
of the first to show evidence that androgens, estrogens, and anti-
estrogens can modulate autoimmunity and disease expression in 
lupus.
The purpose of the current study was to determine the impact 
of early (prepubertal) vs. late (postpubertal) OVX on the disease 
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phenotype and effects on DC development/subsets in female 
lupus-prone mice. We utilized NZM2410 mice, a recombinant 
inbred strain of New Zealand Mixed mice that have a highly pen-
etrant disease with early onset. We have been using these mice for 
many years to study the effects of estrogen receptor alpha (ERα) 
on disease expression. We previously showed that backcrossing 
ERαKO mice onto an NZM2410 background resulted in reduced 
kidney disease and significantly prolonged survival in female, but 
not male mice (4). Of note, ERβKO NZM mice were not similarly 
protected. Thus, it has not been shown that deficiency of ERβ, or 
the early lack of estrogen alone (such as in castrated female B/W 
mice), significantly impacts disease, although we and others have 
shown that deficiency of a functional ERα does impact disease 
(4, 34). Since the timing of castration in males leads to variable 
protection in some lupus strains, we undertook this study in 
WT NZM female mice to ovariectomize either before or after 
puberty (±estrogen replacement in the early OVX group). The 
results are consistent with earlier experiments that showed no 
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significant impact on the development of lupus nephritis with 
OVX alone. Differences were noted, however, in the fact that 
estrogen replacement with a 17β-estradiol pellet, which resulted 
in physiological doses, did not exacerbate disease over WT ani-
mals. Additionally, anti-dsDNA levels were not different between 
the estrogen-treated group and the other groups, but surprisingly, 
were significantly different between the early and late OVX 
groups. This result supports the concept that there exists a time 
point during the transition between adolescence and adulthood, 
as in males, in which hormone levels critically impact develop-
ment of autoimmunity. It is important to separate autoantibody 
production from disease; however, since the animals with higher 
anti-dsDNA levels trended toward reduced kidney disease and 
improved survival. This is similar to what we observed in our 
previous study of NZM ERαKO mice (higher anti-dsDNA, lower 
disease scores), lending credence to the concept of a two-step 
process, whereby autoantibodies are necessary but not sufficient 
for disease (a concept also supported epidemiologically by the 
large number of normal human females that have autoantibodies 
but no evidence of disease).
Since most testosterone in females is secreted by the ovaries, 
it is also important to mention that OVX’d mice have reduced 
levels of both testosterone and estrogen, as evidenced by serum 
levels in our OVX’d animals. One limitation of this study is that 
testosterone and estrogen levels were examined late: at 18 weeks 
(data not shown) and at the terminal endpoint. We chose these 
time points to reflect hormone levels during early and late lupus 
disease onset and to show evidence of successful (long-lasting) 
estradiol replacement. However, the drawback is that these levels 
do not reflect hormone levels during puberty onset, at which 
point testosterone and estrogen levels would have been different 
between the castrated mice (early OVX) and the gonad-intact 
(late OVX) mice. Also, testosterone levels were assessed by RIA, 
which is relatively sensitive and specific, but estrogen levels (using 
ELISA) are notoriously difficult to measure with accuracy. We did 
see lower estrogen levels in our unmanipulated animals than we 
expected, likely due to increasing disease activity and abnormal 
ovarian cycling at that late time point (these animals do not breed 
well beyond 20 weeks).
Importantly, estrogen has different effects depending on tim-
ing, concentration, and cell type. For example, estrogen can help 
break tolerance by promoting survival of autoreactive B cells and 
leading to increased autoantibody production in a murine lupus 
model (19, 35). In other settings, such as experimental autoim-
mune encephalitis (EAE), which is thought to be more T-cell 
driven, estrogen is neuroprotective/anti-inflammatory via ERα 
signaling in astrocytes, which are CNS APCs expressing MHCII, 
B7, and CD40, and are critical for T cell activation (36, 37). It is 
also likely that estrogen impacts immune cell types differentially 
depending on the milieu.
Dendritic cells are immune cells that are important for both 
maintenance of tolerance and an appropriate innate immune 
response. As with most immune cells, the development status 
of DCs is critical in influencing its cellular functions. Immature 
DCs mostly induce tolerance (since they express fewer surface 
molecules that give a second stimulatory signal), whereas 
mature DCs function to induce immune responses by stimu-
lating proliferation of naïve antigen-specific CD4+ T cells or 
CD8+ T cells (38, 39). It is well known that DCs in SLE are 
abnormal in both number and function (40–42). Additionally, 
previously published studies by our lab and others revealed a 
critical role for estradiol and ERα modulating DC number and 
function in normal and lupus-prone animals (22, 25, 26, 43). 
Estrogen also influences maturation and function of human 
monocyte-derived DCs (44). One limitation to this study is that, 
although we focused on DCs, it is likely that our isolated cells, 
whether spleen derived or BM derived, did have some frequency 
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FigUre 5 | spleen Dc flow cytometry in nZM2410 treatment mice. Spleen cell populations were analyzed for absolute number of DCs. Gates were set on live 
singlets that were CD11c+, then subsequently gated on CD8a+ vs. CD11b+. Representative flow cytometry is shown in the four upper panels. (a) O4NP mice had 
a significant reduction in the number of cDCs observed by CD11c+/CD11b+ (vs. NONP, O8NP, and O4 + E2). (B) We also observed an increase in a tolerogenic 
DC subset (CD11c+/CD8a+) in spleens of O4NP mice vs. NONP.
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of monocytes and macrophage present. We and others are mov-
ing toward better markers to gate or sort more specifically on 
DC subsets, but in this experiment, our markers are inadequate 
to identify DCs only.
Because dysregulated DC activation and function are impli-
cated in the pathophysiology of SLE, and estrogen plays a role in 
SLE pathogenesis, this line of study is vital to our understanding 
of sex bias in this disease. In the current study, we observed that 
the single act of ovariectomizing female lupus-prone mice prior 
to puberty resulted in near depletion of absolute numbers of 
CD11c+/CD11b+ DCs from the spleen. This effect appears to be 
due to a lack of estrogen at a critical time point, since replacement 
of estradiol by pellet in early OVX’d mice does not result in the 
same reduction of this DC subset. Perhaps more interesting is 
the observation that a different subset of DCs (CD8a+) were not 
reduced in O4NP mice, and in fact trended toward in increase, 
suggesting that the “imprinting” that took place caused a shift 
in the DC developmental program, rather than simply being a 
survival signal. It is possible that levels of ERα were also altered 
at that time (although we do not have tissue from this early 
time point) since estrogen is known to increase ERα expression. 
One could speculate that when estrogen increases at the time of 
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pubescence, it causes an increase in ERα expression that elicits 
a more proinflammatory environment that then informs DC 
development.
In summary, we investigated the effect of early OVX in WT 
lupus-prone animals and found the disease phenotype to be 
consistent with earlier reports in other lupus strains, except that 
autoantibody levels were actually increased in the (protected) 
early OVX’d mice, at both disease onset and late disease. Although 
there were not significant differences in survival, there was a 
trend toward survival benefit in the early OVX’d animals that 
were not estrogen repleted. These animals also had a significant 
reduction in CD11c+/CD11b+ DCs from spleen, which nor-
mally make up approximately 70% of murine spleen DC (45, 46). 
Conversely, tolerogenic CD11c+CD8a+ DCs were not reduced, 
but rather increased in O4NP mice, suggesting a mechanism for 
the protected phenotype. These data also suggest that the major 
impact of estrogen on DCs is early, specifically during the critical 
hormonal changes that take place at the time of puberty.
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